2015-2017 - Advanced Renal Transplantation - Interactive Teaching Series


Recipient Assessment and Evaluation

9.1 - Recipient Assessment and Evaluation

Presenter: Daniel, Abramowicz, Antwerp, Belgium
Authors: Daniel Abramowicz


Biography

Daniel Abramowicz, MD, PhD, is professor of nephrology and since 2013 head of the department of Nephrology-Hypertension of the Antwerp University Hospital and University of Antwerp (Belgium). He was formerly the head of the renal transplantation program at the Université Libre de Bruxelles, Brussels, Belgium where more than 2500 renal transplantation have been performed.

Dr. Abramowicz has completed a doctoral thesis in 1994, on "Induction of transplantation tolerance in mice". He is author and co-author of more than 200 articles dealing mainly with immunosuppressive regimens in renal transplantation, that have been published among others in Transplantation, Journal of the American Society of Nephrology, American Journal of Transplantation, and Kidney International.

Dr. Abramowicz is Subject Editor for Transplantation for Nephrology, Dialysis and Transplantation. He was a member of the expert group that issued the European Best Practice Guidelines on renal transplantation in 2000 and 2002, and is now member of the European Renal Best Practice advisory board of the ERA-EDTA.

(http://www.european-renal-best-practice.org). He has chaired a working party commissioned by the European Renal Best Practice advisory board to update the European guidelines on renal transplantation. He is chairman of the Descartes ERA-EDTA working group on Transplantation (http://www.era-edta.org/descartes/descartes.htm).

Learning Objectives:

  1. Should we actively screen for presence of malignancy in kidney transplant candidates? Is presence or history of malignancy a contraindication to kidney transplantation?
  2. Under which conditions can HIV infected patients be enrolled on the waiting list?
  3. Should focal segmental glomerulosclerosis (FSGS) as underlying cause of end-stage kidney disease preclude waitlisting for transplantation and does it influence graft and patient survival post-transplantation?
  4. Does pre-transplant tobacco smoking in patients influence patient or graft survival?
  5. Should obesity preclude waitlisting for kidney transplantation and is there a difference in outcomes post-transplantation between those with and without obesity?
  6. How should screening for potential cardiovascular disease in the potential recipient be done in a cost-effective way?
  7. When and for which indications should native nephrectomy be performed in kidney transplant candidates awaiting kidney transplantation?
  8. What are the indications for an additional haemodialysis session in the recipient immediately before the transplantation procedure?
  9. In kidney transplant recipients, what are the effects of using a JJ stent at the time of operation on outcomes?
  10. At what level of GFR should a patient be pre-emptively transplanted?

After the webinar, the attendees should have learned the main issues to be assessed before wait-listing a patient with regards to malignancies, cardiovascular diseases, recurrence of native kidney disease, necessity for pre-transplant nephrectomy, listing of HIV patients, necessity to dialyse the patient pre-Tx, and how to deal with obesity and smoking pre-transplant.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.